Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
EuroIntervention. 2013 May;9 Suppl R:R149-54. doi: 10.4244/EIJV9SRA25.
Pulmonary arterial hypertension (PAH) is a group of diseases related to progressively increasing pulmonary vascular resistance, a high incidence of right ventricular failure and premature death. Only a limited number of pharmaceutical therapies have proven to be beneficial for PAH. These therapies improve symptoms, exercise capacity, and haemodynamics; however, the clinical relevance of these effects has been challenged. Therefore, the effect of currently approved treatment options remains inconclusive. Conversely, several new drugs for various aetiologies and clinical stages are expected to provide significant advances for the treatment of PAH. Moreover, percutaneous pulmonary artery denervation treatment may lead to a new therapeutic orientation in patients with PAH. The aim of this review is to present the new developments in PAH treatment, provide a brief overview of future directions in the field and discuss the potential future prospects of these innovative therapies.
肺动脉高压（PAH）是一组与肺动脉阻力逐渐增加、右心衰竭发生率高和过早死亡相关的疾病。仅有少数药物治疗被证明对 PAH 有益。这些治疗方法可以改善症状、运动能力和血液动力学，但这些效果的临床意义受到了挑战。因此，目前批准的治疗方案的效果仍不确定。相反，针对各种病因和临床阶段的几种新药有望为 PAH 的治疗提供重大进展。此外，经皮肺动脉去神经治疗可能为 PAH 患者带来新的治疗方向。本综述旨在介绍 PAH 治疗的新进展，简要概述该领域的未来方向，并讨论这些创新疗法的潜在前景。
